Evidence map›Paper›PMID 42465584›Full record

ArticleJAC-antimicrobial resistance2026

Comparative evaluation of the activity of novel β-lactam antibiotics against difficult-to-treat

Harry Mystakelis, Ryan K Shields, Amy J Mathers, Yehudit Bergman, Jose M Munita, Sara E Cosgrove, Patricia J Simner, Pranita D Tamma

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JAC-antimicrobial resistance, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Global epidemiology of carbapenem-resistantJAC-antimicrobial resistance · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Harry MystakelisDepartment of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Ryan K ShieldsDepartment of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.ORCID https://orcid.org/0000-0001-9794-5665
Amy J MathersDepartment of Medicine, University of Virginia, Charlottesville, VA, USA.
Yehudit BergmanDepartment of Pediatrics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.ORCID https://orcid.org/0000-0002-4262-7173
Jose M MunitaFacultad de Medicina Clínica Alemana, Universidad del Desarrollo, Instituto de Ciencias e Innovación en Medicina, Santiago, Chile.ORCID https://orcid.org/0000-0002-7870-1056
Sara E CosgroveDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID https://orcid.org/0000-0001-9458-4331
Patricia J SimnerDepartment of Pathology, Mayo Clinic, Rochester, MN, USA.
Pranita D TammaDepartment of Pediatrics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.ORCID https://orcid.org/0000-0002-4143-6324

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: This study aimed to characterize susceptibility profiles of both currently approved and investigational β-lactam agents against difficult-to-treat resistant Patients and methods: A total of 502 consecutive DTR Results: Among the 502 isolates, cefepime-zidebactam exhibited the highest Conclusions: While currently approved β-lactam agents retained activity against many DTR

Identifiers

PMID42465584
PMCPMC13373785

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.